Skip to content
Trial Eligibility
Menu

Clinical Trials Recruiting near Seattle, WA

1,264 clinical trials have a recruiting site within 25 miles of Seattle, Washington, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Studies enrolling near Seattle

Showing 30 studies, nearest first.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 25 mi
  2. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 25 mi
  3. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  4. Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

    NCT03937635

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  5. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    NCT05174169

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  6. Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

    NCT06592924

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  8. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    NCT07222800

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  9. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    NCT04423211

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  10. Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

    NCT04871542

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  11. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    NCT05040360

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  12. Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

    NCT05806515

    • Phase 2
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  13. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  14. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  15. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

    NCT06580314

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  16. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    NCT07013474

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  17. Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

    NCT03067181

    • Phase 3
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  18. A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

    NCT04251052

    • Interventional
    • Ages 35 to 50 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  19. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    NCT04269902

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  20. Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

    NCT06998940

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  21. Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

    NCT07421700

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  22. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  23. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    NCT05642572

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  24. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

    NCT02734537

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  25. Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

    NCT04205968

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  26. Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

    NCT04242095

    • Observational
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  27. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    NCT05561387

    • Phase 3
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  28. Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

    NCT05647265

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  29. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

    NCT06629779

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  30. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    NCT07018869

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi

By condition

Clinical trials in Seattle by condition

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.